From September, Dr Baselga combines the scientific management of the Vall d’Hebron Institute of Oncology (VHIO) with his new appointment at the Hematology & Medical Oncology Division at the Cancer Center of the Massachusetts General Hospital at Harvard Medical School in Boston.
Related Posts
VHIO´s Javier Cortés joins The Lancet Oncology´s International Advisory Board 2014
Javier Cortés, Principal Investigator of VHIO´s Breast Cancer and Melanoma Group, Specialist Physician at the Oncology Department of the Vall…
28 Oct 2013
Abstract submission for the VHIO-Fritz Bender Foundation joint International Symposium on Progress Towards Individualized Cancer Treatments, 07 – 09 November 2013, Barcelona.
Abstract submission and Registration for the VHIO-Fritz Bender Foundation joint International Symposium on Progress Towards Individualized Cancer Treatments, 07 –…
07 Oct 2013
Vall d’Hebron opens the breast cancer center "Endavant i de Cara"
Queen Sofía and Councillor Marina Geli assist at the opening ceremony
07 Sep 2010
The 2013 Georges Mathé Prize awards innovative research into brain tumors
The Prize, supporting translational research of excellence, was established in memory of the pioneer of cancer research in France, Georges…
14 Oct 2013
WIN Consortium and Pfizer Collaborate to Advance Personalized Cancer Care
The Worldwide Innovative Network (WIN) in personalized cancer medicine consortium, of which the Vall d´Hebron Institute of Oncology (VHIO) is…
17 Dec 2012
VHIO scientists and AICR Atlas trekking team to raise funds for cancer research: donate today
Comprised of AICR (now rebranded as Worldwide Cancer Research) donors, supporters, staff and AICR grant holders, some 15 individuals, including VHIO´s…
03 Mar 2014
Josep Tabernero to serve as ESMO President 2018-2019
Source: ESMO Lugano, Switzerland, 23 June 2015 – The European Society for Medical Oncology (ESMO), the leading pan-European organisation in…
23 Jun 2015
Nature Reviews Cancer Viewpoint: Drugging the ´undruggable´ cancer targets
In a Nature Reviews Cancer Viewpoint article published online this week, four leading experts – Chi V. Dang, E. Premkumar…
26 Jun 2017
Studies Report New Findings on Treatment Options for Mesothelioma
High-dose radiotherapy adds no survival benefit after chemotherapy and radical surgery; PD-L1 protein a possible immunotherapy target Is PD-L1 a…
30 Sep 2014
Unmasking the molecular mechanisms driving resistance to targeted therapy against metastatic non-small cell lung cancer
Published as an open access article last week in the flagship journal of the European Society of Medical Oncology (ESMO),…
27 Jul 2017
Josep Tabernero´s candidacy for presidency of the European Society for Medical Oncology and an invitation to ESMO Members to cast their votes before Monday 15 June 2015
VHIO is delighted to announce the candidacy of Josep Tabernero, our Director, for presidency of the European Society for Medical…
01 Jun 2015
Cancer Core Europe´s information hub: website now launched to update on the very latest from this inspired multi-center partnership
Launched in the Autumn of 2014, Cancer Core Europe is a working consortium that represents a critical mass of activity…
20 May 2016
International study signposts promising therapeutic strategy to prevent resistance to RAF-MEK inhibitors
A study published in this month´s Nature Genetics, in which the Vall d’Hebron Institute of Oncology (VHIO) participated, has revealed…
16 Feb 2015
VHIO´s Joan Seoane: Scientific Chair of EACR´s forthcoming conference: Defence is the Best Attack – Immuno-Oncology Breakthroughs, 09 – 11 October 2017, Barcelona, Spain
Tremendous progress marked to-date in more effectively training and harnessing the immune system to recognize, hone in on, and destruct…
24 Apr 2017
PLoS One: Vitamin D Receptor Deficiency Enhances Wnt/ß-Catenin Signaling and Tumor Burden in Colon Cancer
CONFIRMATION THAT VITAMIN D ACTS AS A PROTECTIVE AGENT AGAINST THE ADVANCE OF COLON CANCER A study conducted by…
16 Aug 2011
